Skip to main content
Clinical Trials/NL-OMON51693
NL-OMON51693
Recruiting
Not Applicable

Prospective, Post-market Evaluation of Safety and Efficacy of a Local Osteo-Enhancement Procedure (LOEP) in the Proximal Femur of Women in Europe With Osteoporosis - RECONFIRM

AgNovos Healthcare0 sites30 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
proximal femur with high risk for fragility fracture
Sponsor
AgNovos Healthcare
Enrollment
30
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Sponsor
AgNovos Healthcare

Eligibility Criteria

Inclusion Criteria

  • 1\. Subject is a postmenopausal female (at least 1\-year post menses).
  • 2\. Subject has bone loss in the hip attributable to osteoporosis as defined by
  • a femoral neck DXA T\-score of \-2\.5 or less.
  • 3\. Subject has at least one hip without previous surgery or fracture.
  • 4\. Subject is medically stable from any previous treatment or medical procedure
  • in the opinion of the investigator and with an ASA score of I or II.
  • 5\. Subject has willingness, ability, and commitment to participate in baseline
  • and follow\-up evaluations for the full length of the study.
  • 6\. Subject is capable of giving written informed consent to participate in the

Exclusion Criteria

  • 1\. Subject is less than 3 months removed from having a hip fracture repair or
  • prosthesis or elective Total Hip Arthroplasty (THA).
  • 2\. Subject has progressive increase in hip pain over the previous six (6\)
  • months that in the opinion of the Investigator suggests moderate to severe
  • intra\-articular arthritis, labral tear, extra\-articular soft tissue pathology,
  • referred pain, tumor, stress fracture or infection.
  • 3\. Subject is dependent on the use of a wheelchair or is bedridden.
  • 4\. Subject has albumin corrected serum calcium levels outside the normal lab
  • range or has a pre\-existing calcium metabolism disorder (e.g., hypercalcemia)
  • 5\. Subject has severe renal insufficiency defined as an estimated glomerular

Outcomes

Primary Outcomes

Not specified

Similar Trials